17.05.2019 • NewsCodexisDede WillamsNovartis

Codexis Signs License Deal with Novartis

Codexis Signs License Deal with Novartis (c) Alex_Traksel/Shutterstock
Codexis Signs License Deal with Novartis (c) Alex_Traksel/Shutterstock

US protein engineering company Codexis has signed a platform agreement with Novartis, granting the Swiss pharmaceutical producer a non-exclusive license to its proprietary CodeEvolver protein technology.

Novartis will use the license to develop novel performance enzymes for use in drug manufacture. Upon completion of the technology transfer, the CodeEvolver protein engineering platform will be located at an undisclosed Novartis site.

Terms of the agreement foresee Novartis making an upfront payment, milestone payments upon the satisfactory completion of technology transfer and payments for improvements to the platform technology.

Redwood, California-based Codexis also will be eligible to receive payments for active pharmaceutical ingredients (APIs) produced with enzymes developed by Novartis using the CodeEvolver technology. Additionally, it will receive certain rights for future purchases of enzymes developed and sourced by the drugmaker, using the technology.

John Nicols, Codexis’ president and CEO said Novartis has been a “highly valued customer for nearly a decade, and we’ve been very pleased to see the accelerating and widening of our R&D collaborations together especially over the past several years.”

Novartis, said Nichols, will be the latest leading pharmaceutical company to validate the very wide applicability of enzymatic catalysis across its extensive small molecule drug pipeline.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.